1. Towns J, Webber K. Demonstrating comparability for well-characterized biotechnology products early phase, late phase, and postapproval. BioProcess Int. 2008;32–43.
2. ICH. Comparability of biotechnological/biological products subject to changes in their manufacturing process Q5E November 2004. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf .
3. EMEA. EMEA Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2003.
4. US FDA. Draft guidance for industry, comparability protocols—chemistry, manufacturing, and controls information. 2003. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070545.pdf .
5. US FDA. Draft guidance for industry, established conditions: reportable CMC changes for approved drug and biologic products. 2015. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm448638.pdf .